p. 2518 - 2530
(2018/06/11)p. 2548 - 2551
(2017/05/24)p. 4082 - 4088
(2015/11/11)p. 9568 - 9571
(2013/09/23)p. 6595 - 6599
(2012/09/08)p. 1219 - 1222
(2010/08/20)p. 5277 - 5282
(2010/08/20)p. 8631 - 8638
(2008/03/15)p. 22 - 28
(2007/10/03)p. 790 - 792
(2007/10/03)p. 2776 - 2784
(2007/10/03)(2008/06/13)
p. 10071 - 10074
(2007/10/03)p. 104 - 106
(2007/10/03)(2008/06/13)
p. 911 - 918
(2007/10/02)p. 1693 - 1696
(2007/10/02)p. 1425 - 1428
(2007/10/02)p. 817 - 842
(2007/10/02)(2008/06/13)
p. 5163 - 5166
(2007/10/02)p. 5405 - 5415
(2007/10/02)p. 4463 - 4472
(2007/10/02)p. 27 - 33
(2007/10/02)p. 4129 - 4132
(2007/10/02)p. 4350 - 4360
(2007/10/02)p. 653 - 654
(2007/10/02)p. 3608 - 3611
(2007/10/02)(2008/06/13)
p. 166 - 168
(2007/10/02)formaldehyd
ephedrine
(S)-2-(dimethylamino)propiophenone
methyl iodide
(+/-)-N-methylephedrine
bis-((1Ξ,2S)-2-dimethylamino-1-phenyl-propyl)-ether
(+)-(1S,2S)-N-dodecyl-N,N-dimethylpseudoephedrinium bromide
(+)-2-((1R,2S)-2-dimethylamino-1-phenylpropoxy)pyridine
(1R,2S)-α-<1-(dimethylamino)ethyl>-N-phthalimidobenzylamine
(1S,2S)-1-Phenyl-1-phthalimido-2-(dimethylamino)propane